胆囊癌综合治疗的研究进展
|
摘要
胆囊癌是一种常见的胆管恶性肿瘤,因早期临床缺乏典型表现,晚期治疗效果差,导致该疾病总体预后不良。目前针对胆囊癌的手术治疗、放疗、化疗等治疗方式仍在不断更新。本文就近年来国内外相关文献,对胆囊癌的手术治疗、放疗、化疗等综合治疗手段作一综述,以期望提高对胆囊癌治疗的认识。
The gallbladder is a kind of common bile duct malignant tumor.Due to lack of typical manifestations at early stage and the poor effect of therapies in advanced stage,the overall prognosis of the disease is poor.At present,the therapies for gallbladder cancer such as surgical therapy,radiotherapy,chemotherapy etc,is still continually updating.This article refers to the related literature at home and abroad,to summarise surgical therapy,radiotherapy,chemotherapy etc for the gallbladder cancer,expecting to improve the understanding of gallbladder treatment.
The gallbladder is a kind of common bile duct malignant tumor.Due to lack of typical manifestations at early stage and the poor effect of therapies in advanced stage,the overall prognosis of the disease is poor.At present,the therapies for gallbladder cancer such as surgical therapy,radiotherapy,chemotherapy etc,is still continually updating.This article refers to the related literature at home and abroad,to summarise surgical therapy,radiotherapy,chemotherapy etc for the gallbladder cancer,expecting to improve the understanding of gallbladder treatment.
引文
[1] DONG Jiahong,WANG Jianming,ZENG Jianping.Guidelines for diagnosis and treatment of gallbladder cancer (2015 edition)[J].J Clin Hepatol,2016,32(03):411-419.[董家鸿,王剑明,曾建平.胆囊癌诊断和治疗指南(2015版)[J].临床肝胆病杂志,2016,32(03):411-419.]
[2] TE Sachs,O Akintorin,J Tseng.How should gallbladder cancer be managed[J]?Adv Surg,2018,52(1):89-100.
[3] R Hundal,EA Shaffer.Gallbladder cancer:Epidemiology and outcome[J].Clin Epidemiol,2014,6(1):99-109.
[4] TO Goetze.Gallbladder carcinoma:Prognostic factors and therapeutic options[J].World Journal of Gastroenterology,2015,21(43):12211-12217.
[5] Amin MB,Stephen E,Frederick LG,et al.AJCC cancer staging manual.8th ed[M].New York:Springer,2017:303-309.
[6] Danielle M Hari,J Harrison Howard,Anna M Leung,et al.A 21-year analysis of stage I gallbladder carcinoma:Is cholecystectomy alone adequate[J]?HPB,2012,15(1):40-48.
[7] Eilard M Sternby,L Lundgren,C Cahlin,et al.Surgical treatment for gallbladder cancer-a systematic literature review[J].Scandinavian Journal of Gastroenterology,2017,52(5):505-514.
[8] SE Lee,SW Kim,HS Han,et al.Surgical strategy for T2 gallbladder cancer:Nationwide multicenter survey in Korea[J].Journal of Korean Medical Science,2018,33(28):e186.
[9] Jan Stolarz.Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer:An international multicenter study[J].Annals of Surgery,2015,261(4):733-739.
[10] H Lee,DW Choi,JY Park,et al.Surgical strategy for T2 gallbladder cancer according to tumor location[J].Ann Surg Oncol,2015,22(8):2779-2786.
[11] C Chen,Z Geng,H Shen,et al.Long-term outcomes and prognostic factors in advanced gallbladder cancer:Focus on the advanced T stage[J].Plos One,2016,11(11):e0166361.
[12] Y Zhou,Z Zhang,L Wu,et al.A systematic review of safety and efficacy of hepatopancreatoduodenectomy for biliary and gallbladder cancers[J].HPB (Oxford),2016,18(1):1-6.
[13] Cong LL,Cai ZQ,Peng GM,et al.Decision of surgical approach for advanced gallbladder adenocarcinoma based on a Bayesian network[J].J Surg Oncol,2017,116(8):1123-1131.
[14] Piccolo G,Di VM,Cavallaro A,et al.Lymph node evaluation in gallbladder cancer:Which role in the prognostic and therapeutic aspects.Update of the literature[J].Eur Rev Med Pharmacol Sci,2014,18(2 Suppl):47-53.
[15] Fan DX,Xu RW,Li YC,et al.Impact of the number of examined lymph nodes on outcomes in patients with lymph node-negative gallbladder carcinoma[J].World Journal of Gastroenterology,2018,24(26):2886-2892.
[16] Hiroshi Kurahara,Kosei Maemura,Yuko Mataki,et al.Indication of extrahepatic bile duct resection for gallbladder cancer[J].Langenbecks Archives of Surgery,2018,403(1):1-7.
[17] Lim JH,Chong JU,Kim SH,et al.Role of common bile duct resection in T2 and T3 gallbladder cancer patients[J].Annals of Hepato-Biliary-Pancreatic Surgery,2018,22(1):42-51.
[18] Nigri G,Berardi G,Mattana C,et al.Routine extra-hepatic bile duct resection in gallbladder cancer patients without bile duct infiltration:A systematic review[J].Surgeon,2016,14(6):337-344.
[19] S Patkar,V Ostwal,A Ramaswamy,et al.Emerging role of multimodality treatment in gall bladder cancer:Outcomes following 510 consecutive resections in a tertiary referral center[J].J Surg Oncol,2017,117(3):372-379.
[20] Vikas Ostwal,Rohit Swami,Shraddha Patkar,et al.Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC):A potential way forward[J].Medical Oncology,2018,35(4):57.
[21] Ramaswamy A,Ostwal V,Pinninti R,et al.Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers:A match pair analysis[J].Journal of Hepato-Biliary-Pancreatic Sciences,2017,24(5):262-267.
[22] Y Morine,M Shimada,T Ikemoto,et al.Effect of adjuvant gemcitabine combined with low-dose 5-fluorouracil and cisplatin chemotherapy for advanced biliary carcinoma[J].Anticancer Research,2017,37(11):6421-6428.
[23] C Chen,W Feng,Y Zheng,et al.Intra-arterial chemotherapy improved survival of stage 2-3 gallbladder cancer after curative resection[J].Onco Targets Ther,2018,11(1):2975-2979.
[24] VA Chaudhari,V Ostwal,S Patkar,et al.Outcome of neoadjuvant chemotherapy in "locally advanced/borderline resectable" gallbladder cancer:the need to define indications[J].HPB(Oxford),2018,20(9):841-847.
[25] Guo Y,Chen J,Liu Y,et al.Iodine-125 biliary stent for palliative treatment of locally advanced gallbladder cancer[J].Endoscopy,2010,42(S 02):E259-E260.
[26] V Verma,SM Surkar,ED Brooks,et al.Chemoradiotherapy versus chemotherapy alone for unresected nonmetastatic gallbladder cancer:National practice patterns and outcomes[J].Journal of the National Comprehensive Cancer Network Jnccn,2018,16(1):59-65.
[27] Hoehn RS,Wima K,Ertel AE,et al.Adjuvant therapy for gallbladder cancer:An analysis of the national cancer data base[J].Journal of Gastrointestinal Surgery,2015,19(10):1-8.
[28] I Roa,Toro G De,K Schalper,et al.Overexpression of the HER2/neu gene:A new therapeutic possibility for patients with advanced gallbladder cancer[J].Gastrointestinal Cancer Research Gcr,2014,7(2):42-48.
[29] H Yoshida,K Shimada,T Kosuge,et al.A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status[J].Virchows Arch,2016,468(4):431-439.
[30] M Javle,C Churi,HC Kang,et al.HER2/neu-directed therapy for biliary tract cancer[J].J Hematol & Oncol,2015,8(1):58.
[31] Maolan Li,Fatao Liu,Fei Zhang,et al.Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer:A whole-exome sequencing analysis[J].Gut,2018(1):1-10.
[32] Jin YP,Hu YP,Wu XS,et al.miR-143-3p targeting of ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma[J].Cell Death & Disease,2018,9(2):182.
[33] TT Deleon,DH Ahn,JM Bogenberger,et al.Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma[J].Future Oncology,2018,14(6):553-566.
[34] Urvi A Shah,Amara G Nandikolla,Lakshmi Rajdev.Immunotherapeutic approaches to biliary cancer[J].Current Treatment Options in Oncology,2017,18(7):44.
[2] TE Sachs,O Akintorin,J Tseng.How should gallbladder cancer be managed[J]?Adv Surg,2018,52(1):89-100.
[3] R Hundal,EA Shaffer.Gallbladder cancer:Epidemiology and outcome[J].Clin Epidemiol,2014,6(1):99-109.
[4] TO Goetze.Gallbladder carcinoma:Prognostic factors and therapeutic options[J].World Journal of Gastroenterology,2015,21(43):12211-12217.
[5] Amin MB,Stephen E,Frederick LG,et al.AJCC cancer staging manual.8th ed[M].New York:Springer,2017:303-309.
[6] Danielle M Hari,J Harrison Howard,Anna M Leung,et al.A 21-year analysis of stage I gallbladder carcinoma:Is cholecystectomy alone adequate[J]?HPB,2012,15(1):40-48.
[7] Eilard M Sternby,L Lundgren,C Cahlin,et al.Surgical treatment for gallbladder cancer-a systematic literature review[J].Scandinavian Journal of Gastroenterology,2017,52(5):505-514.
[8] SE Lee,SW Kim,HS Han,et al.Surgical strategy for T2 gallbladder cancer:Nationwide multicenter survey in Korea[J].Journal of Korean Medical Science,2018,33(28):e186.
[9] Jan Stolarz.Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer:An international multicenter study[J].Annals of Surgery,2015,261(4):733-739.
[10] H Lee,DW Choi,JY Park,et al.Surgical strategy for T2 gallbladder cancer according to tumor location[J].Ann Surg Oncol,2015,22(8):2779-2786.
[11] C Chen,Z Geng,H Shen,et al.Long-term outcomes and prognostic factors in advanced gallbladder cancer:Focus on the advanced T stage[J].Plos One,2016,11(11):e0166361.
[12] Y Zhou,Z Zhang,L Wu,et al.A systematic review of safety and efficacy of hepatopancreatoduodenectomy for biliary and gallbladder cancers[J].HPB (Oxford),2016,18(1):1-6.
[13] Cong LL,Cai ZQ,Peng GM,et al.Decision of surgical approach for advanced gallbladder adenocarcinoma based on a Bayesian network[J].J Surg Oncol,2017,116(8):1123-1131.
[14] Piccolo G,Di VM,Cavallaro A,et al.Lymph node evaluation in gallbladder cancer:Which role in the prognostic and therapeutic aspects.Update of the literature[J].Eur Rev Med Pharmacol Sci,2014,18(2 Suppl):47-53.
[15] Fan DX,Xu RW,Li YC,et al.Impact of the number of examined lymph nodes on outcomes in patients with lymph node-negative gallbladder carcinoma[J].World Journal of Gastroenterology,2018,24(26):2886-2892.
[16] Hiroshi Kurahara,Kosei Maemura,Yuko Mataki,et al.Indication of extrahepatic bile duct resection for gallbladder cancer[J].Langenbecks Archives of Surgery,2018,403(1):1-7.
[17] Lim JH,Chong JU,Kim SH,et al.Role of common bile duct resection in T2 and T3 gallbladder cancer patients[J].Annals of Hepato-Biliary-Pancreatic Surgery,2018,22(1):42-51.
[18] Nigri G,Berardi G,Mattana C,et al.Routine extra-hepatic bile duct resection in gallbladder cancer patients without bile duct infiltration:A systematic review[J].Surgeon,2016,14(6):337-344.
[19] S Patkar,V Ostwal,A Ramaswamy,et al.Emerging role of multimodality treatment in gall bladder cancer:Outcomes following 510 consecutive resections in a tertiary referral center[J].J Surg Oncol,2017,117(3):372-379.
[20] Vikas Ostwal,Rohit Swami,Shraddha Patkar,et al.Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC):A potential way forward[J].Medical Oncology,2018,35(4):57.
[21] Ramaswamy A,Ostwal V,Pinninti R,et al.Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers:A match pair analysis[J].Journal of Hepato-Biliary-Pancreatic Sciences,2017,24(5):262-267.
[22] Y Morine,M Shimada,T Ikemoto,et al.Effect of adjuvant gemcitabine combined with low-dose 5-fluorouracil and cisplatin chemotherapy for advanced biliary carcinoma[J].Anticancer Research,2017,37(11):6421-6428.
[23] C Chen,W Feng,Y Zheng,et al.Intra-arterial chemotherapy improved survival of stage 2-3 gallbladder cancer after curative resection[J].Onco Targets Ther,2018,11(1):2975-2979.
[24] VA Chaudhari,V Ostwal,S Patkar,et al.Outcome of neoadjuvant chemotherapy in "locally advanced/borderline resectable" gallbladder cancer:the need to define indications[J].HPB(Oxford),2018,20(9):841-847.
[25] Guo Y,Chen J,Liu Y,et al.Iodine-125 biliary stent for palliative treatment of locally advanced gallbladder cancer[J].Endoscopy,2010,42(S 02):E259-E260.
[26] V Verma,SM Surkar,ED Brooks,et al.Chemoradiotherapy versus chemotherapy alone for unresected nonmetastatic gallbladder cancer:National practice patterns and outcomes[J].Journal of the National Comprehensive Cancer Network Jnccn,2018,16(1):59-65.
[27] Hoehn RS,Wima K,Ertel AE,et al.Adjuvant therapy for gallbladder cancer:An analysis of the national cancer data base[J].Journal of Gastrointestinal Surgery,2015,19(10):1-8.
[28] I Roa,Toro G De,K Schalper,et al.Overexpression of the HER2/neu gene:A new therapeutic possibility for patients with advanced gallbladder cancer[J].Gastrointestinal Cancer Research Gcr,2014,7(2):42-48.
[29] H Yoshida,K Shimada,T Kosuge,et al.A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status[J].Virchows Arch,2016,468(4):431-439.
[30] M Javle,C Churi,HC Kang,et al.HER2/neu-directed therapy for biliary tract cancer[J].J Hematol & Oncol,2015,8(1):58.
[31] Maolan Li,Fatao Liu,Fei Zhang,et al.Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer:A whole-exome sequencing analysis[J].Gut,2018(1):1-10.
[32] Jin YP,Hu YP,Wu XS,et al.miR-143-3p targeting of ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma[J].Cell Death & Disease,2018,9(2):182.
[33] TT Deleon,DH Ahn,JM Bogenberger,et al.Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma[J].Future Oncology,2018,14(6):553-566.
[34] Urvi A Shah,Amara G Nandikolla,Lakshmi Rajdev.Immunotherapeutic approaches to biliary cancer[J].Current Treatment Options in Oncology,2017,18(7):44.